Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HER-2/neu intracellular domain protein + Polysaccharide-K + Trastuzumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HER-2/neu intracellular domain protein | HER-2 ICD Peptide|HER-2-neu ICD Protein | HER-2/neu intracellular domain protein is the cytoplasmic domain of the Her-2 protein, which may enhance the T-cell response against Her-2 expressing tumor cells when administered with trastuzumab (NCI Drug Dictionary). | ||
Polysaccharide-K | Krestin|PSK | Krestin (polysaccharide-K) is a mushroom-derived immunomodulator that has been demonstrated to reduce immunosuppression and enhance anti-tumor immunity. Krestin has also been shown to reduce proliferation and induce apoptosis in tumor cells (PMID: 22139128). | ||
Trastuzumab | Herceptin | Anti HER2 | HER2 (ERBB2) Antibody 77 | Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|